Kalshi is taking the worst possibilities in a sick child’s life and preparing to turn them into someone else’s financial position. Joshua Pederson, a Boston University professor whose twelve-year-old son is in a clinical trial for an aggressive tumor growing inches below his heart, wrote this week that the plan is “enraging.” He is right. His family has endured a recurrence, a frightening prognosis, and the grinding uncertainty of a clinical trial combining chemotherapy and immunotherapy; the early results have been mixed, every cycle carries present side effects, and the consequences may follow his son for years. Kalshi’s first proposed contracts include wagers on whether an anti-cancer drug will receive FDA approval and whether an Alzheimer’s drug trial will meet its endpoints. Its CEO, Tarek Mansour, calls this “surfacing information.”
The steelman earns its paragraph. Clinical-trial data is locked behind institutional walls. Pharmaceutical companies have reasons to overstate promise. Families like the Pedersons can be left choosing among trials for which they feel “ill-prepared.” Mansour’s argument is that a continuously updated public probability might weigh the evidence more honestly than a trial sponsor’s preferred message. The information argument is not nothing.
But it is not everything.
The second paragraph is where the abstraction devours the human. I traded agricultural futures for a living. The mechanism is elegant: the rancher becomes a number, the harvest becomes a contract, and the man in the field is replaced by a ticker on a screen. The trader who prices the corn never meets the family that grew it. Now apply that machinery to a cancer trial—to parents grinding through cycle after cycle, not knowing whether a treatment will save their child—and tell me what information the market has surfaced that justifies the price.
The price becomes the reality. The patient becomes the contract.
A prediction market does not become morally clean because it uses the language of probability. A wager on whether a cancer treatment succeeds is still a wager on an outcome that families experience as survival, relapse, or death. The decimal points do not make the stakes abstract. They merely make them easier to package, price, and sell.
When this boy’s cancer returned, his doctors presented several trials for which he was eligible. Choosing among them was a terrifying experiment, even with an extremely qualified oncology team. No responsible parent needs a public betting line pretending to replace that expertise. Families need better access to clinical data, clearer disclosure, stronger independent review, and medical care. They do not need their fear converted into liquidity.
Kalshi is not yet offering bets on treatments for children. The company says it will not allow them. That limitation does not answer the larger problem, because the architecture is the point. Kalshi’s first proposed contracts include a wager on whether an anti-cancer drug will gain FDA approval and another on whether an Alzheimer’s trial will meet its goals—real trials, real patients, real families praying for good news. Mansour has imagined a world in which “any difference in opinion” is wagerable.
Children’s treatments are not on the menu—yet. The company has not ruled out the principle that would put them there. The regulatory environment will not necessarily stop it. The Trump administration is going to remarkable lengths to shield prediction markets from state regulation. The same platform Meta’s Mark Zuckerberg has been courting for acquisition has already expanded from elections to flight cancellations. A cancelled flight is an inconvenience. A failed cancer trial is not.
Prediction markets are not magically wiser than the people trading in them. They can be thin, distorted, and vulnerable to participants with better information or simply greater resources. In medicine, a bad signal does not end with a mistaken forecast. It can influence public confidence, research incentives, and the willingness of patients to enter trials whose success is already uncertain. The market does not merely describe hope. It can alter the conditions under which hope survives.
This is the same logic behind Kalshi’s expanding catalogue, from health outcomes to flight cancellations: take an uncertain event, turn it into a tradable instrument, and call the resulting market a source of public knowledge. It is the rentier’s oldest instinct. If something exists, find a way to extract rent from it.
The family farm became a commodity position. The nursing home became a balance sheet. The local newspaper became a liquidation event. Now the machinery reaches for the last institution it has not yet priced: the outcome of a sick person’s hope.
The conservative tradition has a vocabulary for this, if anyone still remembers it. Pius XI wrote in Quadragesimo Anno that it is “an injustice and at the same time a grave evil and disturbance of right order” to assign to a greater and higher association what lesser and subordinate organizations can do. Subsidiarity is not a slogan for shrinking government while leaving every private empire untouched. It is a judgment about where human beings possess the knowledge, duty, and moral standing to decide.
In a child’s cancer treatment, the lesser institutions are the family, the oncologist, the parish that surrounds them, and the community that shows up. The decision belongs at the lowest competent level: the physician who knows the patient, the family who knows the child. A distant trading platform does not know more simply because it can produce a price faster.
The doctor-patient bond is a mediating institution. The family is a mediating institution. The parish that brings meals to the house where a child is sick is a mediating institution. Each is weakened when a financial platform declares that their terror, hope, and grinding patience are merely a “difference of opinion” waiting to be monetized.
The ticker does not know it is pricing a child. That is the mechanism’s elegance and its obscenity.
This is also where the movement that calls itself conservative should recognize its own betrayal. Conservatism once claimed to defend the family, the settled institution, the local bond, and the human scale against abstract power. Yet when a rentier platform turns medical uncertainty into an asset class, the defenders of “freedom” discover that freedom means nothing more than the right of a stranger to profit from another family’s catastrophe. They have conserved nothing—not the family, not the doctor’s judgment, not the parish, not even the boundary between knowledge and gambling.
The answer is not to make the state a wiser gambler. It is to keep clinical data open to patients, doctors, and researchers; require clear disclosure and independent review; protect trial participants from financial manipulation; and preserve the institutions that know the person behind the outcome. The counter-model is subsidiarity: knowledge held close to the patient, authority answerable to the family, medicine ordered toward healing rather than speculation, and a community that carries its suffering together.
Clinical trials should produce knowledge for patients, doctors, and researchers. They should not become another arena in which suffering is treated as an asset class. Kalshi is not merely predicting the future. It is teaching us to call extraction information—and asking us to place a bet on whether someone else’s child will live.